The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia

European Journal of Neurology

Volumn 21, Issue 12, 2014, Pages 1486-e98

  Delnooz, C C S ^a   Veugen, L C ^a   Pasman, J W ^a   Lapatki, B G ^b   van Dijk, J P ^b,c   van de Warrenburg, B P C ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

Author keywords

Botulinum toxin; Cervical dystonia; Electromyography; Motor endplate zone

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CERVICAL DYSTONIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELECTROMYOGRAPHY; FEMALE; HIGH DENSITY SURFACE ELECTROMYOGRAPHY; HUMAN; MALE; MASTOID; MOTOR ENDPLATE ZONE; MUSCLE ACTION POTENTIAL; MUSCLE LENGTH; NERVE ENDING; PRIORITY JOURNAL; STERNOCLEIDOMASTOID MUSCLE; TREATMENT DURATION; VERTEBRA; VISION; DRUG EFFECTS; MIDDLE AGED; NECK MUSCLE; TORTICOLLIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ENDPLATE; NECK MUSCLES; NEUROMUSCULAR AGENTS; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84916216545     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12517     Document Type: Article

References (26)

1. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088-1091.
2. Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 2012; 259: 2519-2526.
3. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005; 1: CD003633.
4. Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996; 46: 1158-1160.
5. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon 2009; 54: 683-689.
6. Borodic G. Therapeutic botulinum toxin. Lancet 1994; 344: 1370.
7. Childers MK. Targeting the neuromuscular junction in skeletal muscles. Am J Phys Med Rehabil 2004; 83(Suppl. 10): S38-S44.
8. Delagi EF, Iazzetti J, Perotto AO, Morrison D. Anatomical Guide for the Electromyographer: The Limbs and Trunk, 2nd edn. Springfield, IL: Thomas, 1980.
9. Werdelin L, Dalager T, Fuglsang-Frederiksen A, et al. The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study. Clin Neurophysiol 2011; 122: 2305-2309.
10. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil 2009; 90: 9-16.
11. Lim EC, Quek AM, Seet RC. Accurate targeting of botulinum toxin injections: how to and why. Parkinsonism Relat Disord 2011; 17(Suppl. 1): S34-S39.
12. Bakheit AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf 2006; 1: 271-279.
13. Brans JW, de Boer IP, Aramideh M, Ongerboer de Visser BW, Speelman JD. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 1995; 242: 529-534.
14. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990; 12: 392-399.
15. Lapatki BG, van Dijk JP, van de Warrenburg BP, Zwarts MJ. Botulinum toxin has an increased effect when targeted toward the muscle's endplate zone: a high-density surface EMG guided study. Clin Neurophysiol 2011; 122: 1611-1616.
16. Zwarts MJ, Stegeman DF. Multichannel surface EMG: basic aspects and clinical utility. Muscle Nerve 2003; 28: 1-17.
17. Lapatki BG, Oostenveld R, Van Dijk JP, Jonas IE, Zwarts MJ, Stegeman DF. Topographical characteristics of motor units of the lower facial musculature revealed by means of high-density surface EMG. J Neurophysiol 2006; 95: 342-354.
18. Masuda T, Miyano H, Sadoyama T. The propagation of motor unit action potential and the location of neuromuscular junction investigated by surface electrode arrays. Electroencephalogr Clin Neurophysiol 1983; 55: 594-600.
19. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42: 878-882.
20. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996; 46: 1382-1386.
21. Consky E, Basinki A, Belle L. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 1990; 40(Suppl. 1): 445.
22. Falla D, Dall'Alba P, Rainoldi A, Merletti R, Jull G. Location of innervation zones of sternocleidomastoid and scalene muscles - a basis for clinical and research electromyography applications. Clin Neurophysiol 2002; 113: 57-63.
23. Lee JH, Lee BN, Han SH, An XC, Chung RH. The effective zone of botulinum toxin A injections in the sternocleidomastoid muscle. Surg Radiol Anat 2011; 33: 185-190.
24. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008; 23: 510-517.
25. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005; 20: 783-791.
26. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997; 12: 89-94.